Ian Michael McGowan

10PUBLICATIONS
51CO-AUTHORS
Preventative health careInnate immunityPharmacogenomicsEpidemiological modellingMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Nov 09, 2026
A Randomized, Double-Blind Phase 1 Safety and Pharmacokinetic Study of Q-Griffithsin Douche Administered Rectally to HIV-1 Seronegative Adults (the PREVENT Study).

|Mar 23, 2026
Mucosal tenofovir 1% gel stimulates cell proliferation and type I/III interferon pathways.

Sean M Hughes, Fernanda L Calienes, Claire N Levy

|Mar 04, 2025
Safety, immunogenicity and effect on viral rebound of HTI vaccines combined with a TLR7 agonist in early-treated HIV-1 infection: a randomized, placebo-controlled phase 2a trial.

Lucia Bailón, José Moltó, Adrian Curran

|Oct 27, 2022
Safety, immunogenicity and effect on viral rebound of HTI vaccines in early treated HIV-1 infection: a randomized, placebo-controlled phase 1 trial.

Lucia Bailón, Anuska Llano, Samandhy Cedeño

|Sep 20, 2021
An Open-Label Pharmacokinetic and Pharmacodynamic Assessment of Tenofovir Gel and Oral Emtricitabine/Tenofovir Disoproxil Fumarate.

Ian M McGowan, Ratiya Pamela Kunjara Na Ayudhya, Rhonda M Brand

|Aug 13, 2021
A Randomized, Open-Label, Crossover Phase 1 Safety and Pharmacokinetic Study of Oral Maraviroc and Maraviroc 1% Gel (the CHARM-03 Study).

Ian M McGowan, Sylvain Chawki, Craig W Hendrix

Pageof 2

Frequent Collaborators

3 joint publications

Ross D Cranston

2 joint publications

Christian Brander

2 joint publications

Yovaninna Alarcón-Soto

2 joint publications

Beatriz Mothe